Menopause International > Volume 15, Number 3 > Pp. 100-106

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Benster, B. Articles by Studd, J. PubMed PubMed Citation Social Bookmarking                      What's this?

Original articles

Double-blind placebo-controlled study to evaluate the effect of pro-juven progesterone cream on atherosclerosis and bone density

Beverly Benster ^* , Adam Carey ^*, Fred Wadsworth ^*, Maura Griffin , Andrew Nicolaides  and John Studd ^*

^* Chelsea and Westminster Hospital, London, UK
Imperial College, London, UK

Correspondence: Beverly Benster, Email: bensterb{at}live.co.uk
Objective. To establish whether treatment for three years with pro-juven progesterone cream affects progression of atherosclerotic plaques or bone density in postmenopausal women.

Design. Randomized double-blind placebo-controlled trial.

Sample. One hundred and thirty-one healthy postmenopausal women aged between 50 and 75 years with at least one asymptomatic arterial plaque visible on ultrasound of the carotid or femoral bifurcation.

Methods. Women were randomly allocated to receive pro-juven progesterone cream, 20 mg twice daily, or placebo, for three years.

Main outcome measure. Rate of change of plaque thickness, intima-media thickness and bone density of lumbar spine and femoral neck.

Results. There was no difference between the groups.

Conclusion. Pro-juven progesterone cream 20 mg twice daily did not affect progression of asymptomatic atherosclerosis or deterioration in bone density over three years.

Key Words: Progesterone cream • atherosclerosis • plaque • bone density • ultrasound • menopause

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?